logo

CLRB

Cellectar
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About CLRB

Cellectar Biosciences, Inc.

A late-stage biopharmaceutical company focused on targeted treatments for cancer

Pharmaceutical
Invalid Date
08/15/2014
NASDAQ Stock Exchange
11
12-31
Common stock
100 Campus Drive, Florham Park, New Jersey 07932
--
Cellectar Biosciences, Inc., formerly known as Novelos Therapeutics, Inc., was founded in Delaware in June 1996. On February 11, 2014, the company changed its name to its current name. The company is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of cancer therapies. The company's core objective is to utilize proprietary phospholipid ether drug conjugate delivery platforms to develop PDCs that are designed to specifically target cancer cells and provide better efficacy and better safety due to fewer off-target effects.

Earnings Call

Company Financials

EPS

CLRB has released its 2025 Q1 earnings. EPS was reported at -0.14, versus the expected -0.16, beating expectations. The chart below visualizes how CLRB has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime